Iridium containing hydrosilylation catalysts and compositions containing the catalysts
US-9221041-B2 · Dec 29, 2015 · US
Gold(III) complexes as anticancer agents and a method of treating cancer
US10385072B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10385072-B2 |
| Application number | US-201715654784-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 20, 2017 |
| Priority date | Jul 20, 2017 |
| Publication date | Aug 20, 2019 |
| Grant date | Aug 20, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Gold(III) complexes containing mixed ligands. A method of treating cancer with these complexes is disclosed. The complexes are cytotoxic to prostate, breast, ovarian, and Hodgkin lymphoma cancer cell lines. These complexes were either more potent than cisplatin or had similar potency to cisplatin.
First claim
Opening claim text (preview).
The invention claimed is: 1. A gold(III) complex selected from the following: 2. A pharmaceutical composition, comprising: the gold(III) complex of claim 1 ; and at least one pharmaceutically acceptable carrier and/or excipient. 3. The pharmaceutical composition of claim 2 , wherein the at least one pharmaceutically acceptable carrier and/or excipient is selected from the group consisting of water, an organic solvent, an animal fat, a vegetable fat, a vegetable oil, and a polymer. 4. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises 0.1-10 wt % of the gold(III) complex, based on a total weight of the pharmaceutical composition. 5. A method for treating cancer, comprising: administering an effective amount of the gold(III) complex of claim 1 to a subject in need thereof, wherein the cancer is selected from the group consisting of prostate cancer, lung cancer, breast cancer, ovarian cancer, and Hodgkin lymphoma. 6. The method of claim 5 , wherein the effective amount is in a range of 1-100 mg/kg body weight of the subject. 7. The method of claim 5 , wherein the cancer is at least one selected from the group consisting of prostate cancer, lung cancer, breast cancer, ovarian cancer, and Hodgkin lymphoma. 8. The method of claim 5 , wherein the cancer is prostate cancer which is resistant to androgen deprivation therapy. 9. The method of claim 5 , wherein the cancer is resistant to at least one platinum-based chemotherapy drug. 10. The method of claim 9 , wherein the cancer is ovarian cancer. 11. A method for inhibiting growth of cancer cells, comprising: contacting a cytotoxic amount of the gold(III) complex of claim 1 with the cancer cells, wherein the cancer cells are selected from the group consisting of prostate cancer, lung cancer, breast cancer, ovarian cancer, and Hodgkin lymphoma cells. 12. The method of claim 11 , wherein the cancer cells are from at least one cell line selected from the group consisting of PC3, MCF-7, A2780, A2780cis, A2780CP-16, H460, A549, H226, H838, H157, H1975, H2122, SKLU1, H1299, and L-540.
Assignees
Inventors
Classifications
- C07F1/005Primary
without C-Metal linkages · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10385072B2 cover?
- Gold(III) complexes containing mixed ligands. A method of treating cancer with these complexes is disclosed. The complexes are cytotoxic to prostate, breast, ovarian, and Hodgkin lymphoma cancer cell lines. These complexes were either more potent than cisplatin or had similar potency to cisplatin.
- Who is the assignee on this patent?
- Univ King Fahd Pet & Minerals
- What technology area does this patent fall under?
- Primary CPC classification C07F1/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).